JP2023539525A5 - - Google Patents

Info

Publication number
JP2023539525A5
JP2023539525A5 JP2023514116A JP2023514116A JP2023539525A5 JP 2023539525 A5 JP2023539525 A5 JP 2023539525A5 JP 2023514116 A JP2023514116 A JP 2023514116A JP 2023514116 A JP2023514116 A JP 2023514116A JP 2023539525 A5 JP2023539525 A5 JP 2023539525A5
Authority
JP
Japan
Prior art keywords
days
use according
sequence
weeks
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023514116A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539525A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/074314 external-priority patent/WO2022049220A2/en
Publication of JP2023539525A publication Critical patent/JP2023539525A/ja
Publication of JP2023539525A5 publication Critical patent/JP2023539525A5/ja
Pending legal-status Critical Current

Links

JP2023514116A 2020-09-02 2021-09-02 抗体療法 Pending JP2023539525A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20194018 2020-09-02
EP20194018.6 2020-09-02
PCT/EP2021/074314 WO2022049220A2 (en) 2020-09-02 2021-09-02 Antibody therapy

Publications (2)

Publication Number Publication Date
JP2023539525A JP2023539525A (ja) 2023-09-14
JP2023539525A5 true JP2023539525A5 (https=) 2024-09-09

Family

ID=72340230

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023514116A Pending JP2023539525A (ja) 2020-09-02 2021-09-02 抗体療法

Country Status (7)

Country Link
US (1) US20230310599A1 (https=)
EP (1) EP4208200A2 (https=)
JP (1) JP2023539525A (https=)
CN (1) CN116472060A (https=)
BR (1) BR112023003868A2 (https=)
IL (1) IL300835A (https=)
WO (1) WO2022049220A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022013797A (es) 2020-05-08 2022-11-30 Genmab As Anticuerpos biespecificos contra cd3 y cd20.
US20220313816A1 (en) * 2021-04-01 2022-10-06 Human Vaccines Project Compositions and methods for antibody-as-adjuvant vaccines and therapeutics

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
WO2009117616A2 (en) * 2008-03-19 2009-09-24 Yale University Carbon nanotube compositions and methods of use thereof
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
DK2786762T3 (da) 2008-12-19 2019-05-06 Macrogenics Inc Kovalente diabodies og anvendelser deraf
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CN103068847B (zh) 2010-08-24 2019-05-07 罗切格利卡特公司 可活化的双特异性抗体
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
CN104736174B (zh) * 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
WO2014163684A1 (en) * 2013-04-03 2014-10-09 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
ME03675B (me) 2013-07-05 2020-10-20 Genmab As Humanizovana ili himerna anтi-cd3 antiтela
US9483549B2 (en) 2013-09-30 2016-11-01 Microsoft Technology Licensing, Llc Persisting state at scale across browser sessions
AU2016378573A1 (en) * 2015-12-22 2018-07-19 Regeneron Pharmaceuticals, Inc. Bispecific anti-CD20/anti-CD3 antibodies to treat acute lymphoblastic leukemia
AU2018227428A1 (en) 2017-02-28 2019-10-17 Bristol-Myers Squibb Company Use of anti-CTLA-4 antibodies with enhanced ADCC to enhance immune response to a vaccine
US12390514B2 (en) * 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
KR102602329B1 (ko) * 2018-05-23 2023-11-16 화이자 인코포레이티드 Cd3에 특이적인 항체 및 이의 용도
CA3101271A1 (en) * 2018-05-24 2019-11-28 Janssen Biotech, Inc. Anti-cd3 antibodies and uses thereof
PE20211916A1 (es) * 2018-05-24 2021-09-28 Janssen Biotech Inc Agentes aglutinantes del psma y usos de estos
WO2019241216A1 (en) * 2018-06-14 2019-12-19 Bioatla, Llc Multi-specific antibody constructs
TW202504917A (zh) * 2018-06-21 2025-02-01 美商再生元醫藥公司 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法
JP7410143B2 (ja) * 2018-11-01 2024-01-09 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 二重特異性抗体及びその用途

Similar Documents

Publication Publication Date Title
CA2422002C (en) Vaccine
US20170080064A1 (en) Methods and compositions for increasing a t-effector cell to regulatory t cell ratio
Jemon et al. An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy
JP2021531345A (ja) 腫瘍ワクチン接種に用いるための組合せ製品
JP2023539525A5 (https=)
US12358996B2 (en) Fusion proteins for immunotherapy against cancer and infectious diseases
KR102728174B1 (ko) 백신 보조제로서 gm3 강글리오시드의 합성 변이체를 포함하는 나노입자
US20230310599A1 (en) Antibody therapy
US20240409608A1 (en) Combination therapies against cancer and infectious diseases
JP2005519023A (ja) 腫瘍の治療のための免疫療法的併用
Sharif et al. Bioengineered ClearColi™-derived outer membrane vesicles displaying CT26 neoepitopes as potent vaccine adjuvants against colon carcinoma in a preventive mouse model
CA3107263A1 (en) Nasal vaccine that induces cell-mediated immunity
CN121405821B (zh) 一种融合蛋白及在制备治疗或预防乙肝病毒产品中的应用
Ito et al. Programmable Antigen‐Specific Immunity via Self‐Adjuvanting Nanovaccines Co‐Delivering Immune Modulators
Mandal Cancer Immunotherapy: Extending New Horizons in Cancer Treatment
HK1136785A (en) Vaccine against streptococcus pneumoniae